http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2010527908-A
Outgoing Links
Predicate | Object |
---|---|
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7042 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7048 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7068 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4375 |
classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-47 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-513 |
filingDate | 2007-12-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 2010-08-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | JP-2010527908-A |
titleOfInvention | Combination comprising CNDAC (2'-cyano-2'-deoxy-N4-palmitoyl-1-beta-D-arabinofuranosyl-cytosine) and a cytotoxic agent |
abstract | According to a first aspect of the present invention, there is provided 2′-cyano-2′-deoxy-N 4 -palmitoyl-1-β-D-arabinofuranosyl-cytosine, a metabolite thereof, or a pharmaceutically acceptable salt thereof. , (A) an HDAC inhibitor, and (b) a combination comprising a topoisomerase inhibitor selected from etoposide, topotecan, and SN-38 or a cytotoxic drug selected from a prodrug thereof. In a second aspect, (i) 2′-cyano-2′-deoxy-N 4 -palmitoyl-1-β-D-arabinofuranosyl-cytosine, a metabolite thereof, or a pharmaceutically acceptable salt thereof (Ii) (a) an HDAC inhibitor and (b) a cytotoxic agent selected from etoposide, topotecan, and a topoisomerase inhibitor selected from SN-38 or a prodrug thereof, simultaneously, sequentially, or It relates to a pharmaceutical product comprising as a combined preparation for separate use. A third aspect comprises 2′-cyano-2′-deoxy-N 4 -palmitoyl-1-β-D-arabinofuranosyl-cytosine, a metabolite thereof, or a pharmaceutically acceptable salt thereof; Administering to the subject simultaneously, separately or sequentially a) an HDAC inhibitor, and (b) a topoisomerase inhibitor selected from etoposide, topotecan, and SN-38 or a prodrug thereof. To a method of treating a proliferative disorder. A fourth aspect of the invention is the subject 2′-cyano-2′-deoxy-N 4 -palmitoyl-1-β-D-arabinofuranosyl-cytosine, its metabolites or pharmaceutically acceptable The use of salt in the preparation of a medicament for treating cutaneous T-cell lymphoma (CTCL). |
isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-H0928446-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2014526558-A |
priorityDate | 2006-12-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 303.